Vaxxinity has to lower bar for IPO attempt
To view this email as a web page, click here

Today's Rundown

Featured Story

Organon keeps pedal to the metal, buying up Forendo in 3rd deal since spinning out of Merck

The rat-a-tat-tat pace of dealmaking at Merck spinout Organon continues. Having identified more than 140 clinical-phase assets in its wheelhouse, Organon has pulled the trigger on its third deal in six months by agreeing to buy Forendo Pharma for an initial $75 million.

read more

Top Stories

Genentech, Novome team up to study seaweed-controlled oral cell therapies in IBD

Are seaweed-controlled oral cell therapies the future of inflammatory bowel disease therapy? That is the question posed by the latest deal from Genentech, which is teaming up with Novome Biotechnologies to study a novel approach to the indication. 

read more

Vaxxinity, hoping to turn bodies into their own drug factories, makes a subdued Wall Street debut

Immunotherapeutic vaccine developer Vaxxinity, with an eye on COVID and some serious CNS diseases, has pulled off a fairly small IPO.

read more

Sponsored: A New Reference Model for Clinical Trial Recruitment, Enrollment and Retention Success

Rare diseases demand a modern recruitment approach grounded in uncovering the ideal, medically-eligible patient population with the highest propensity for study enrollment and retention.

read more

Shasqi snatches $50M for chemotherapy-boosting treatments thanks to Arcus, NGM execs

Shasqi has collected $50 million in a series B financing to fuel the path through the clinic. The funding round was driven by a cohort of private investors including Arcus Biosciences President Juan Jaen, Ph.D., and Bill Rieflin, executive chairman of the board at NGM Biopharmaceuticals.

read more

Acrivon Therapeutics secures $100M to give Eli Lilly cancer drug another try, fund 2 solid tumor candidates

Prexasertib has been investigated in nearly 20 clinical studies since being discovered by Array in the 1990's, but Eli Lilly decided to part ways with it in 2019. Now, Acrivon Therapeutics has $100 million in funding to give the drug another shot at potentially treating solid cancers through an equity and licensing agreement with Lilly.

read more

Eli Lilly touts long-term safety data for Olumiant amid classwide scrutiny on JAK meds

Eli Lilly’s Olumiant has been dragged into a classwide safety review of JAK medicines that originated from Pfizer’s Xeljanz. Hoping to convince doctors that its offering doesn’t share the problems at the same magnitude, the Indianapolis pharma is turning to long-term data.

read more

Startup Regulonix pursues non-opioid pain drug that indirectly blocks a key ion channel

The NaV1.7 ion channel is expressed in some neurons and plays a critical role in sensing pain, but suppressing it head-on has proven tricky. A drug that blocks the channel through two related proteins relieved pain in several animal models, a University of Arizona team reported, and Regulonix has licensed it for development.

read more

Taking a bite out of Big Tech: Outgoing J&J CEO Gorsky takes health tech talents to Apple

As Apple continues to accelerate its push into healthcare, the Big Tech company will have a seasoned veteran of the health tech world on its side.

read more

Express Scripts launches option for employers to cover over-the-counter COVID-19 tests

Plans can set the copayment for the test at either a discounted rate or a $0 copay, Express Scripts said.

read more

Resources

Whitepaper: Medable was able to cut costs in multiple clinical trials by over US$25,000,000

Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper.

Webinar: Using Next Best to Elevate your Omnichannel Marketing Strategy

Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making.

Webinar: The Faster Path From Pre-Filled Syringe to Auto-Injector

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.

Whitepaper: Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Whitepaper: How the Chronic Insomnia Market Raises Big Questions About Digital Therapeutics

Paper describing how the chronic insomnia market offers big lessons for any biopharma company thinking about getting into digital therapeutics in any therapeutic area.

Whitepaper: A Checklist for eCOA Solution Deployment

Every detail is important when selecting a new eCOA solution; learn more about the current eCOA landscape, best practices, and crucial considerations for successful eCOA solution deployment in this white paper.

2021 Report: Clinical Trial Management in a Post-Pandemic World

New market research provides valuable insight into the impact of adaptations made in clinical trials during the pandemic.

Whitepaper: Enhance the cost-effectiveness of your cGMP chemical supply chain

Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific

Paid Marketplace: Online Graduate Programs Designed for Your Career

Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more.

eBook: Get solutions to market faster

Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization.

Events